News &amp; Updates

Polytrauma patients with obesity appear to have a lower risk of death and shorter length of hospital stays, suggests a study.

Obesity in polytrauma patients appears protective vs death

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

In the first interim analysis of the phase III KEYNOTE-689 trial, pembrolizumab improves event-free survival (EFS) and major pathological response (mPR) rate, independent of CPS*, when added to standard-of-care (SoC) treatment for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

The use of the injectable extended-release naltrexone for alcohol use disorder in patients with advanced alcohol-associated liver disease (ALD) does not appear to carry a substantial hepatotoxicity or liver decompensation risk, according to a study.

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

The link between microbes and the gut is being brought to light with the power of AI.

Former Dean of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK), Choh-Ming Li Professor of Medicine and Therapeutics, codirector of Microbiota I-Center (MagIC), Gastroenterologist

The link between microbes and the gut is being brought to light with the power of AI.

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

Darolutamide demonstrated clinically meaningful delays in pain progression and deterioration of important patient-relevant health-related quality of life (HRQoL) outcomes vs placebo in men with metastatic hormone-sensitive prostate cancer (mHSPC), according to phase III ARANOTE trial findings presented at ASCO 2025. [ASCO 2025, abstract 5004]

ARANOTE: Darolutamide positively impacts HRQoL in men with mHSPC

24 Jun 2025

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.

BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines

24 Jun 2025

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

23 Jun 2025 by

In patients with low-risk, early-stage breast cancer who have undergone breast-conserving surgery, partial-breast radiotherapy (RT) is as safe and efficacious as whole-breast RT, according to 10-year data from the phase III IMPORT LOW trial.

Long-term data solidify partial-breast RT as standard of care in low-risk early breast cancer

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

A recent study has provided data bolstering the current recommendation of using carvedilol to prevent a first decompensation of cirrhosis in patients with compensated cirrhosis.

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025 by

The use of penpulimab, in combination with gemcitabine and cisplatin or carboplatin, as first-line treatment for recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) provides statistically significant and clinically meaningful benefit, according to a study presented at AACR 2025.

Penpulimab extends survival in R/M nasopharyngeal carcinoma

Metabolic burden ups risk of death in CHB patients with SLD

Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.

Metabolic burden ups risk of death in CHB patients with SLD